Chinese biotech giant WuXi AppTec raises 2026 outlook after profit surge
WuXi AppTec raised its full-year revenue guidance after its net profit surged 62.4 per cent in the first nine months of 2026, while revenue rose 38.6 per cent on strong demand for its drug development and manufacturing services. The Chinese pharmaceutical research services provider’s net profit reached 19.16 billion yuan (US$2.87 billion) for the nine months ended September 30, compared with…
We haven't written up this one. SCMP Business has the full story — the link below goes straight to it.
